MapLight Therapeutics
MPLTMPLT · Stock Price
Historical price data
Overview
MapLight Therapeutics is on a mission to redefine the standard of care for brain disorders by moving beyond broad neuromodulation to precise, circuit-specific therapeutics. The company has built a robust pipeline of six drug candidates, with its most advanced programs in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. Its strategy is anchored in a proprietary discovery platform co-founded by optogenetics pioneer Karl Deisseroth, which integrates cutting-edge technologies to translate deep neuroscience insights into targeted medicines for conditions like autism, Parkinson's, and schizophrenia.
Technology Platform
The MAP (Molecular and Anatomical Phenotyping) platform integrates optogenetics, transcriptomics, and STARmap spatial profiling to causally identify dysfunctional neural circuits and their unique molecular targets for drug development.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ML-004 (IR)/(ER) tablet | Autism Spectrum Disorder | Phase 2 | |
| Placebo + ML-007C-MA BID + ML-007C-MA QD | Schizophrenia | Phase 2 | |
| ML-004 (IR)/(ER) tablet + ML-004 Placebo | Autism Spectrum Disorder | Phase 2 | |
| ML-007C-MA | Psychosis Associated With Alzheimer's Disease | Phase 2 | |
| ML-007C-MA | Schizophrenia | Phase 2 |
